- Home
- DIBS vs NTHI Comparison
DIBS vs NTHI Comparison
Compare DIBS & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DIBS | NTHI |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.0M | 139.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | DIBS | NTHI |
|---|---|---|
| Price | $5.23 | $4.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 161.2K | 85.8K |
| Earning Date | 05-08-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $89,620,000.00 | N/A |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $1.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.54 | N/A |
| 52 Week Low | $2.50 | $3.20 |
| 52 Week High | $6.62 | $12.99 |
Technical Indicators
Market Signals| Indicator | DIBS | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 70.66 | 44.72 |
| Support Level | $4.92 | $4.17 |
| Resistance Level | $6.18 | $5.78 |
| Average True Range (ATR) | 0.25 | 0.53 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 97.72 | 24.57 |
Price Performance
Historical ComparisonAbout DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.